These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29979295)

  • 41. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding the safety of the new ultra long acting basal insulin.
    Ramachandran A; Gupta V; Kesavadev J; Kalra S
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
    Sleeman A; Odom J; Schellinger M
    Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
    [No Abstract]   [Full Text] [Related]  

  • 46. Insulin degludec: a novel basal insulin analogue.
    Goldman-Levine JD; Patel DK; Schnee DM
    Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
    Brown MA; Davis CS; Fleming LW; Fleming JW
    J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of insulin development: focus on key parameters.
    Tibaldi JM
    Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating the managed care implications of longer-acting basal insulin analog therapies.
    Logan T; Daisy B
    Am J Manag Care; 2018 Mar; 24(6 Suppl):S93-S101. PubMed ID: 29620817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC; Shau WY; Lai MS
    Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
    Landstedt-Hallin L; Gundgaard J; Ericsson Å; Ellfors-Zetterlund S
    Curr Med Res Opin; 2017 Apr; 33(4):647-655. PubMed ID: 28035840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
    Muñoz Torres M
    Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review.
    Hangaard S; Jensen MH
    Curr Osteoporos Rep; 2021 Dec; 19(6):637-643. PubMed ID: 34741730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of the pharmacological properties of insulin degludec and their clinical relevance.
    Haahr H; Heise T
    Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials.
    Liu W; Yang X; Huang J
    Int J Endocrinol; 2018; 2018():8726046. PubMed ID: 29721018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.
    Dankers M; Hek K; Nelissen-Vrancken M; Houweling ST; Mantel-Teeuwisse A; van Dijk L
    Br J Gen Pract; 2022 Jun; 72(719):e430-e436. PubMed ID: 35606162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.